Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.
Africa
HIV drug resistance
first-line
treatment failure
virological failure
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
23
04
2021
accepted:
18
10
2021
pubmed:
11
11
2021
medline:
15
4
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
HIV virological failure remains a major threat to programme success in sub-Saharan Africa. While HIV drug resistance (HIVDR) and inadequate adherence are the main drivers of virological failure, the individual, clinical and health system characteristics that lead to poor outcomes are not well understood. The objective of this paper is to identify those characteristics among people failing first-line antiretroviral therapy (ART). We enrolled a cohort of adults in HIV care experiencing virological failure on first-line ART at five sites and used standard statistical methods to characterize them with a focus on three domains: individual/demographic, clinical, and health system, and compared each by country of enrolment. Of 840 participants, 51% were women, the median duration on ART was 3.2 years [interquartile range (IQR) 1.1, 6.4 years] and the median CD4 cell count prior to failure was 281 cells/µL (IQR 121, 457 cells/µL). More than half of participants [53%; 95% confidence interval (CI) 49-56%] stated that they had > 90% adherence and 75% (95% CI 72-77%) took their ART on time all or most of the time. Conversely, the vast majority (90%; 95% CI 86-92%) with a completed genotypic drug resistance test had any HIV drug resistance. This population had high health system use, reporting a median of 3 (IQR 2.6) health care visits and a median of 1 (IQR 1.1) hospitalization in the preceding 6 months. Patients failing first-line ART in sub-Saharan Africa generally report high rates of adherence to ART, have extremely high rates of HIV drug resistance and utilize significant health care resources. Health systems interventions to promptly detect and manage treatment failure will be a prerequisite to establishing control of the HIV epidemic.
Identifiants
pubmed: 34755438
doi: 10.1111/hiv.13203
pmc: PMC9010349
mid: NIHMS1750165
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-484Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007387
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124718
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069412
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI143470
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI098558
Pays : United States
Informations de copyright
© 2021 British HIV Association.
Références
PLoS One. 2019 Feb 5;14(2):e0211344
pubmed: 30721233
J Infect Dis. 2001 May 1;183(9):1328-35
pubmed: 11294663
J Int AIDS Soc. 2019 Nov;22(11):e25409
pubmed: 31691521
AIDS. 2016 Apr 24;30(7):1121-9
pubmed: 26785125
HIV Med. 2012 Jan;13(1):62-72
pubmed: 21848790
HIV Clin Trials. 2017 Jul;18(4):149-155
pubmed: 28720039
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Int AIDS Soc. 2017 Jul 19;20(1):21803
pubmed: 28777506
Lancet HIV. 2015 Jul;2(7):e271-8
pubmed: 26423252
PLoS One. 2013 Oct 16;8(10):e77691
pubmed: 24147057
AIDS Res Ther. 2014 Jan 23;11(1):9
pubmed: 24456757
Am J Epidemiol. 2020 Aug 1;189(8):811-819
pubmed: 32219384
South Afr J HIV Med. 2020 Sep 04;21(1):1102
pubmed: 32934832
PLoS One. 2019 Aug 28;14(8):e0220337
pubmed: 31461455
Nat Commun. 2020 Dec 1;11(1):5922
pubmed: 33262331
HIV Med. 2014 Sep;15(8):478-87
pubmed: 24589279
Lancet HIV. 2020 Apr;7(4):e229-e237
pubmed: 32105625
Int Health. 2017 Jul 1;9(4):206-214
pubmed: 28810670
AIDS Behav. 2018 Jul;22(7):2368-2379
pubmed: 29779162
HIV Clin Trials. 2016 Jul 29;17(5):173-180
pubmed: 27472067
J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):247-254
pubmed: 30422906
Antivir Ther. 2012;17(2):377-86
pubmed: 22297391
J Int AIDS Soc. 2017 Mar 3;20(1):21218
pubmed: 28362063
AIDS. 2018 Jul 31;32(12):1551-1561
pubmed: 29746295
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
Curr Opin HIV AIDS. 2020 Jan;15(1):13-18
pubmed: 31764197
AIDS Behav. 2017 Jul;21(7):2135-2140
pubmed: 28361454
AIDS. 2020 Aug 1;34(10):1559-1566
pubmed: 32675566
PLoS One. 2011 Mar 09;6(3):e17518
pubmed: 21408071
J Int AIDS Soc. 2019 Feb;22(2):e25232
pubmed: 30746898
BMC Infect Dis. 2017 Aug 22;17(1):582
pubmed: 28830382
J Antimicrob Chemother. 2016 Oct;71(10):2918-27
pubmed: 27342546
Lancet Infect Dis. 2019 Jul;19(7):e246-e252
pubmed: 30902440
Clin Infect Dis. 2010 Mar 1;50(5):779-86
pubmed: 20121574
AIDS Patient Care STDS. 2013 Dec;27(12):657-68
pubmed: 24320011
PLoS Med. 2020 Feb 25;17(2):e1003037
pubmed: 32097428
Clin Infect Dis. 2013 Nov;57(10):1489-96
pubmed: 23946221
PLoS One. 2009 Sep 29;4(9):e7196
pubmed: 19787058
HIV Med. 2020 Aug;21(7):457-462
pubmed: 32495515
AIDS. 2014 Sep 10;28(14):2097-107
pubmed: 24977440
Clin Infect Dis. 2006 Jun 1;42(11):1608-18
pubmed: 16652319
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
Antivir Ther. 2011;16(6):853-61
pubmed: 21900717